TECX

Tectonic TherapeuticB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

Current thesis

TECX has moved from a one-asset story toward a two-clinical-asset setup, with TX45 carrying the main upside into the 2026 APEX readout and TX2100 adding optionality after first-human dosing began in February 2026 [#8-K-2026-02-26].

Posture

Constructive

Lead driver

Momentum

What changed

Momentum remains the lead driver in the composite, 7D delta -2.0.

What can break

Earlier-than-expected financing or ATM usage if burn rises or timelines extend

Momentum

Value

Sentiment

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $31.00 · Bull $48.00 · Bear $16.00

Data freshness

Prices

As of 2026-06-02

Fundamentals

As of 2026-06-01 • Vendor: Data Vendor v1

Scores

As of 2026-06-02 • Model: HYBRID_IC_RP

AI Memo

As of 2026-04-15 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-06-02

Supporting evidence

What

Grade B · Constructive

Confidence Medium · Net Neutral

Target $78.25

Why

Momentum68 · Δ7d -2.0

Value41 · Δ7d +0.1

Sentiment61 · Δ7d +4.3

So what

Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Lead driver: Momentum · See technicals

Momentum

34% active weight

Current posture

7d trendSoftening

Δ7d

-2.0

Δ21d

+25.3

Value

32% active weight

Current posture

7d trendFlat

Δ7d

+0.1

Δ21d

+0.2

Sentiment

33% active weight

Current posture

7d trendImproving

Δ7d

+4.3

Δ21d

+2.9

Why this grade

Composite grade B. Momentum 68.2 / Value 41.1 / Sentiment 61.1

Fundamentals (TTM)

As of 2026-06-01

Market Cap

$545.13M

Beta

1.59

Shares Out

18.72M

P/E (TTM) · Derived

-7.2

P/S (TTM)

P/FCF (TTM) · Derived

-8.07

Rev YoY

EPS YoY

+15.4%

Gross Margin

Op Margin

Net Debt

-$140.36M

Current Ratio

29.15

As of 2026-06-02 • Updated nightlySource: Internal modelMethodology